Online citations, reference lists, and bibliographies.

An Open-label Trial Of Risperidone And Fluoxetine In Children With Autistic Disorder

Avinash Desousa
Published 2010 · Medicine, Psychology
Cite This
Download PDF
Analyze on Scholarcy
Share
Objective: Various studies have shown the effectiveness of risperidone and fluoxetine in the management of behavioral problems in autism. Aim: The purpose of this study was to compare these two drugs in the management of behavioral problems in autism. Materials and Methods: Forty children with autism were divided into 2 groups in a 16-week open trial that compared these two drugs. Parents rated the children using the Aberrant Behavior Checklist (ABC) and the Conners′ Parent Rating Scale – Revised (CPRS-R). The author rated the children using the Children's Psychiatric Rating Scale and Clinical Global Impression (CGI) Scale. Results: The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy. When the two drugs were compared, fluoxetine showed greater improvement in stereotypy, while both drugs showed improvement on the general autism scale; and on anger, hyperactivity and irritability scales. Conclusions: In this open trial, both drugs were well tolerated and appeared to be beneficial in the treatment of common behavioral problems in children with autism. Further controlled and double-blind studies in larger samples are warranted.
This paper references
10.1097/00008480-199608000-00008
The serotonin system in autism.
E. Cook (1996)
Child and Adolescent Psychopharmacology. Lippincott: Williams and Wilkins; 2001. Desousa: Risperidone versus fluoxetine
WH Green (2010)
Lippincott: Williams and Wilkins
W H Green (2001)
10.1089/cap.1999.9.93
Risperidone-induced hepatotoxicity in children and adolescents? A chart review study.
E. Szigethy (1999)
10.1016/S0140-6736(03)14236-5
Targeted treatments for symptom domains in child and adolescent autism
E. Hollander (2003)
10.1089/cap.2000.10.79
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
A. Zuddas (2000)
10.1097/00004583-199705000-00021
Risperidone in adolescents with schizophrenia: an open pilot study.
J. Armenteros (1997)
10.1177/026988110201600113
A systematic review of the use of atypical antipsychotics in autism
L. Barnard (2002)
10.1089/cap.2000.10.259
Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
A. Martin (2000)
10.1089/cap.1996.6.177
Use of risperidone in pervasive developmental disorders: a case series.
S. Fisman (1996)
10.1089/104454602760386932
A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders.
J. Couturier (2002)
Research Units on Pediatric Psychopharmacology Autism Network (RUPPN)
(2002)
10.1097/00004583-199105000-00029
Fluoxetine in autism with depression.
M. Ghaziuddin (1991)
Children ’ s Psychiatric Rating Scale
B Fish (1998)
10.1097/01.chi.0000153229.80215.a0
An open-label trial of escitalopram in pervasive developmental disorders.
T. Owley (2005)
10.1002/1097-4679(198809)44:5<708::AID-JCLP2270440507>3.0.CO;2-T
Behavioral assessment of psychopathology in children: infantile autism.
John E. Overall (1988)
10.1023/A:1022602400621
The Revised Conners' Parent Rating Scale (CPRS-R): Factor Structure, Reliability, and Criterion Validity
C. Conners (1998)
10.1016/S0022-3476(61)80261-8
Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children.
R. Schain (1961)
10.1023/A:1025854532079
Risperidone and Explosive Aggressive Autism
J. Horrigan (1997)
10.3928/0048-5713-20030401-04
Child and Adolescent Psychopharmacology
R. Balon (2003)
10.1016/0278-5846(95)00026-R
World wide use of psychotropic drugs in child and adolescent psychiatric disorders
J. G. Simeon (1995)
Diagnostic and Statistical Manual of Psychiatric Disorders -IV (DSM-IV)
10.1097/00004583-199409000-00010
Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study.
B. Black (1994)
10.1089/104454603322163871
Drug-induced disinhibition in psychiatrically hospitalized children.
G. Carlson (2003)
10.1517/14656566.2.4.587
Pharmacotherapeutic management of autism
David J. Posey (2001)
Rockville (Maryland) Department of Health, Education and Welfare
W Guy (1976)
10.1007/978-1-4613-8774-9
Psychopharmacology of the developmental disabilities
M. Aman (1988)
10.1097/00004583-199207000-00024
Fluoxetine treatment of children and adults with autistic disorder and mental retardation.
E. Cook (1992)
Fluoxetine and methylphenidate combination in the treatment of attention deficit disorder in children
GD Gammon (1994)
Measurement of side effects including tardive dyskinesia.
M. Campbell (1985)
10.1089/104454602760386923
A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder.
A. Hardan (2002)
10.1016/S0891-4222(01)00091-9
Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education.
E. C. Brown (2002)
10.1089/cap.1997.7.109
Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.
E. S. Brodkin (1997)
10.1097/00004583-199902000-00004
Paroxetine in autism.
D. Posey (1999)
10.1111/J.1469-8749.1998.TB15414.X
Effects of fluoxetine treatment in young children with idiopathic autism.
G. Delong (1998)
10.1097/00004583-199804000-00014
An open trial of risperidone in young autistic children.
Rob Nicolson (1998)
10.1089/cap.2005.15.116
Medication patterns in patients with autism: temporal, regional, and demographic influences.
M. Aman (2005)
10.1097/00004583-199001000-00008
Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience.
M. Riddle (1990)
Sertraline response in adults with mental retardation and autistic disorder.
J. Hellings (1996)
10.1017/S109285290002215X
The pharmacological treatment of autistic spectrum disorders.
T. Owley (2002)
10.1007/BF02172145
Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders
C. Lord (1994)
10.1023/A:1022234605695
Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
A. Martin (2003)



This paper is referenced by
10.1097/JCP.0000000000000688
Risperidone and Cardiometabolic Risk in Children and Adolescents: Clinical and Instrumental Issues
Emilia Matera (2017)
HVP21323 76..92
Laura C. Politte (2014)
10.1089/act.2015.21208
Clinical Roundup: Selected Treatment Options for Autism
(2015)
10.1097/YIC.0b013e328362497b
Tolerability and safety profile of risperidone in a sample of children and adolescents
Lucia Margari (2013)
10.1007/s10803-018-3850-0
Dietary Patterns and Anthropometric Measures of Indian Children with Autism Spectrum Disorder
Seema Siddiqi (2019)
10.1007/978-81-322-3619-1_17
Pediatric Psychopharmacology: Perspectives from Low Resource Countries
Devashish Konar (2016)
10.1007/s10803-012-1750-2
Ethical Considerations in Conducting Research on Autism Spectrum Disorders in Low and Middle Income Countries
Tamara C. Daley (2013)
10.1007/978-1-4939-0506-5_9
Pharmacotherapy of Behavioral Symptoms and Psychiatric Comorbidities in Adolescents and Adults with Autism Spectrum Disorders
Carolyn A. Doyle (2014)
10.4103/0976-3147.193530
Risperidone-induced Enuresis in a 12-year-old Child
Reetika Dikshit (2017)
Andhra Pradesh Journal of Psychological Medicine Ips-ap Chapter Executive Council Members Original Articles Delay in First Psychiatric Consultation and Its Reasons
Rajshekhar Bipeta (2012)
10.1517/14656566.2016.1154536
Psychopharmacological interventions in autism spectrum disorder
Robert E. Accordino (2016)
10.1007/7854_2015_5003
Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.
Tatiana M Kazdoba (2016)
10.1016/j.jaac.2014.10.002
Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.
Karsten Gjessing Jensen (2015)
10.1097/HRP.0000000000000030
Psychopharmacological Interventions in Autism Spectrum Disorder
Laura C. Politte (2014)
Semantic Scholar Logo Some data provided by SemanticScholar